FDA approves Shire's Vyvanse for ADHD

02/24/2007 | MSNBC

Shire PLC says the amphetamine-based drug is meant to supplant its top-selling Adderall XR when that drug goes off patent in 2009. Shire says it believes a new formulation, which makes the drug inactive unless swallowed, will curtail potential abuse of the drug.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY